Literature DB >> 16258121

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

Christopher G Willett, Yves Boucher, Dan G Duda, Emmanuelle di Tomaso, Lance L Munn, Ricky T Tong, Sergey V Kozin, Lucine Petit, Rakesh K Jain, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Kenneth S Cohen, David T Scadden, Alan J Fischman, Jeffrey W Clark, David P Ryan, Andrew X Zhu, Lawrence S Blaszkowsky, Paul C Shellito, Mari Mino-Kenudson, Gregory Y Lauwers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16258121     DOI： 10.1200/JCO.2005.02.5635

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  150 in total

1.  Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

Authors:  John F de Groot; Yuji Piao; Hai Tran; Mark Gilbert; Hua-Kang Wu; Jun Liu; B Nebiyou Bekele; Tim Cloughesy; Minesh Mehta; H Ian Robins; Andrew Lassman; Lisa DeAngelis; Kevin Camphausen; Alice Chen; W K A Yung; Michael Prados; Patrick Y Wen; John V Heymach
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 3.  Bevacizumab.

Authors:  Filis Kazazi-Hyseni; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2010-08-05

4.  Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Authors:  Sung-Suk Chae; Walid S Kamoun; Christian T Farrar; Nathaniel D Kirkpatrick; Elisabeth Niemeyer; Annemarie M A de Graaf; A Gregory Sorensen; Lance L Munn; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 5.  Differential macrophage programming in the tumor microenvironment.

Authors:  Brian Ruffell; Nesrine I Affara; Lisa M Coussens
Journal:  Trends Immunol       Date:  2012-01-23       Impact factor: 16.687

Review 6.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

Review 8.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

9.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors:  Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

10.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.